Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings (NASDAQ: LNTH) has announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Jefferies Virtual Healthcare Conference on June 3 at 10:30 a.m. ET. Investors can access the live webcast of the presentation on the Company’s website. A replay will be available for 30 days post-event. Lantheus is a leader in imaging diagnostics and therapeutics, providing products like DEFINITY® and RELISTOR® to address serious medical conditions.
Lantheus Holdings (NASDAQ: LNTH) reported Q1 2021 revenue of $92.5 million, marking a 2.0% increase from Q1 2020. Net income rose to $9.0 million, equivalent to $0.13 per diluted share, compared to $3.3 million or $0.08 last year. However, adjusted diluted EPS fell 86.3% to $0.05 from $0.36. Operating cash flow was $9.8 million, and free cash flow increased to $7.3 million.
The company updates its FY 2021 revenue guidance to $390 million - $400 million and Q2 revenue between $93 million - $97 million.
EXINI Diagnostics AB, a subsidiary of Lantheus Holdings (NASDAQ: LNTH), has received CE Mark clearance for its AI-based software, aPROMISE, in Europe. This innovative tool enhances quantitative assessment of PSMA PET/CT in oncology, demonstrating a high reproducibility with an intraclass correlation coefficient of 0.99. aPROMISE aims to improve efficiency and accuracy in imaging assessments, particularly in detecting prostate cancer. With potential U.S. approval expected later this year, aPROMISE is designed to strengthen Lantheus's portfolio and assist clinicians in patient management.
Lantheus Holdings (NASDAQ: LNTH) announced a collaboration with Allegheny Health Network (AHN) to develop a treatment for xerostomia using Lantheus' microbubbles combined with AHN's ultrasound-assisted non-viral gene transfer (UAGT) technology. Xerostomia, often caused by cancer treatments, leads to severe dry mouth and related health issues. The partnership aims to leverage UAGT's potential for long-term xerostomia relief, with Lantheus supplying microbubbles. AHN will handle the development and commercialization of the treatment.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced its upcoming conference call and webcast scheduled for May 4, 2021, at 8:00 a.m. ET, to discuss the financial and operational results for Q1 2021. Interested parties can join by dialing the provided numbers or through the company's website. Lantheus is known for its innovative imaging diagnostics and therapeutics, including products like DEFINITY® and TechneLite®. The company is headquartered in North Billerica, Massachusetts, with operations in multiple locations.
Lantheus Holdings (NASDAQ: LNTH) announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko, both reporting to Chief Medical Officer Istvan Molnar, MD. Dr. Denes brings 25 years of urology experience and industry expertise from Amgen and Blue Earth Diagnostics, while Dr. Teslenko has over 17 years in drug development and clinical research in oncology, previously with GlaxoSmithKline. Their combined expertise aims to advance Lantheus' pipeline, particularly in prostate cancer radiopharmaceuticals, reinforcing the company’s commitment to innovative diagnostics and therapeutics.
Lantheus Holdings (NASDAQ: LNTH) has announced the retirement of Michael P. Duffy, General Counsel, effective June 4, 2021, after over 13 years with the company. Duffy will continue in an advisory role, with Daniel Niedzwiecki taking over his responsibilities. Duffy expressed pride in his contributions to the transformation of Lantheus into a publicly traded company since its IPO in 2015, noting a sevenfold increase in market cap. The transition comes on the heels of the successful integration of the Progenics acquisition.
Lantheus Holdings has acquired exclusive worldwide rights to develop and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics. This innovative agent targets fibroblast activation protein (FAP), which is overexpressed in various tumors, making it a promising biomarker for precision medicine in oncology. Noria will conduct early clinical development, while Lantheus plans to integrate the agent into its imaging portfolio for academic and pharmaceutical use. Financial terms include an upfront fee, milestone payments, and royalties upon commercialization.
Lantheus Holdings (NASDAQ: LNTH) presented updated biochemical tumor marker data from its Phase 2 trial of AZEDRA® at ENDO 2021. The trial showed significant reductions in tumor biomarkers in patients with advanced pheochromocytoma and paraganglioma. Notably, 80% of patients had a reduction in Chromogranin A levels, with responses correlating with the study's endpoints. AZEDRA remains the first approved treatment for these conditions, with the data reinforcing its clinical utility. However, caution is advised due to potential severe side effects, including myelosuppression and radiation risks.
Lantheus Holdings (NASDAQ: LNTH) announced the publication of pivotal studies for PyL™, a PET imaging agent targeting prostate-specific membrane antigen (PSMA). Results from the OSPREY Phase 2/3 trial and the CONDOR Phase 3 trial were published in respected journals, indicating high predictive values for locating prostate cancer. The data supports FDA review for marketing authorization. The OSPREY trial achieved a specificity of 96-99% and sensitivity of 93-99%. The CONDOR trial reported a Correct Localization Rate of 84.8% to 87.0% and 63.9% of patients had treatment plan changes based on imaging results.
FAQ
What is the current stock price of Lantheus Holdings (LNTH)?
What is the market cap of Lantheus Holdings (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
